DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Jagasia M, Perales MA, Schroeder MA. et al.
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Blood 2020;
135 (20) 1739-1749
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.